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Early rule- out pathways for myocardial 
infarction: is observational 
data enough?
Kuan Ken Lee   ,1 Nicholas L Mills   1,2
Symptoms suggestive of an acute coronary 
syndrome remain one of the most common 
reasons for emergency department presen-
tations worldwide.1 However, only a small 
proportion of patients have myocardial 
infarction, and therefore strategies to 
expedite evaluation are valuable both for 
patients and healthcare systems.2
The introduction of high- sensitivity 
cardiac troponin assays that are able to 
measure very low concentrations of cardiac 
troponin at high- precision has been one of 
the most important innovations in cardio-
vascular diagnostics in recent years.3 
There is now substantial evidence demon-
strating the excellent prognostic value of 
very low troponin concentrations, which 
have been incorporated into multiple early 
rule- out pathways for myocardial infarc-
tion.4 While some of these pathways are 
now recommended by national and inter-
national guidelines and have been imple-
mented in clinical care, their performance 
has largely been evaluated in observational 
studies, and the true safety and efficacy 
of implementing these approaches is not 
known.5 Many of the observational studies 
were performed in small, selected patient 
populations and based on a retrospective 
analysis where the pathways were not used 
to guide clinical care.4 Conversely, there 
have been very few randomised controlled 
trials evaluating the safety and efficacy of 
these approaches.3 6
It is in this context that the LoDED 
(Limit of Detection and ECG Discharge) 
investigators must be congratulated for 
successfully delivering a prospective 
multicentre randomised controlled trial 
to evaluate the effectiveness of imple-
menting an early rule- out pathway in 
adults with suspected cardiac chest pain 
and no evidence of myocardial ischaemia 
on the ECG.7 The LoDED strategy iden-
tified patients as eligible for discharge 
from the emergency department where 
the troponin concentration at presenta-
tion was below a high- sensitivity cardiac 
troponin I or T assays limit of detection. 
They recruited a total of 629 patients 
across eight hospitals in England and 
Wales and randomised these patients 1:1 
to either the early rule- out strategy or 
usual care using an open- label, blinded 
endpoint, parallel group design. In this 
trial, all sites used high- sensitivity cardiac 
troponin assays in usual care (five sites 
used a troponin T assay and three used a 
troponin I assay). However, it is important 
to note that in half the sites, the limit of 
detection was already in use as part of 
the usual care pathway in combination 
with a validated risk stratification score. 
The primary outcome was discharge from 
hospital within 4 hours of arrival without 
a major adverse cardiac event (MACE), 
which was defined as cardiac death, type 
1 myocardial infarction or emergency 
coronary revascularisation within 30 days. 
All MACE outcomes were adjudicated by 
a panel blinded to the study group and 
presentation troponin concentrations. The 
4- hour timepoint was prespecified because 
this is an important operational standard 
for emergency departments within the 
National Health Service in the UK.
The LoDED trial reported that a 
larger proportion of patients were safely 
discharged within 4 hours in the group 
randomised to the LoDED strategy 
compared with usual care (46% vs 37%, 
respectively) although this was not signifi-
cantly different (pooled adjusted OR, 1.58 
(95% CI 0.84 to 2.98)). There was also 
no difference in the rates of MACE at 30 
days in patients randomised to the LoDED 
strategy compared with usual care (8% vs 
5% respectively, OR 1.50 95% CI 0.76 
to 3.02)), median time to discharge (4.4 
(3.2–6.8) hours vs 5.0 (3.4–7.4)), patient 
satisfaction (51 (44–55) vs 50 (44–55)) or 
secondary care costs up to 30 days post 
discharge (£429 (£302 to £651) vs £527 
(£391 to £720)).
There are a number of potential reasons 
why the trial did not demonstrate a mean-
ingful difference in efficacy between the 
LoDED strategy and usual care. First, half 
the participating hospital sites already used 
the limit of detection threshold as part 
of the usual care early rule- out pathway, 
which attenuated the effectiveness of the 
intervention. Indeed, there was significant 
heterogeneity across the eight hospital 
sites for the primary outcome (I2=61%, 
p=0.01). Interestingly, in a subgroup anal-
ysis, there was a significant improvement 
in efficacy in sites that did not already use 
the limit of detection in usual care (OR 
2.87 (1.07–7.69)), but there was no differ-
ence in sites that did use this threshold 
(OR 0.93 (0.54–1.59)). However, as the 
authors acknowledged, this is not the only 
explanation for the overall result, because 
only two out of the four sites that did not 
use the limit of detection in their usual care 
improved. Other factors such as differ-
ences in intensity of each department, 
patient population and other local poli-
cies might have influenced length of stay 
across hospital sites. Second, it is possible 
that the trial was underpowered to observe 
a significant difference between the 
rule- out strategies. The trial was powered 
to detect a 9% difference in the primary 
outcome based on an anticipated primary 
outcome rate of 17% in the LoDED arm 
vs 9% in the usual care arm. In fact, the 
trial observed a much higher rate of early 
discharge within 4 hours in both arms 
(46% in those randomised to the LoDED 
strategy vs 37% in those randomised to 
standard care). This meant that the trial 
would have required approximately twice 
the sample size of over 1200 patients to 
detect a 9% difference in efficacy with 
90% power and two- sided alpha of 0.05. 
Third, the trial population was relatively 
young (mean age of 53.8±16.1 years) and 
low- risk (prior history of coronary artery 
disease (13%), diabetes mellitus (10%), 
hypertension (27%), hyperlipidaemia 
(15%)) in comparison with other studies 
of unselected patients presenting to the 
emergency department with suspected 
acute coronary syndrome.3 It is possible 
that the recruitment process has intro-
duced a degree of selection bias. These 
low- risk patients may have presented 
with lower diagnostic complexity, which 
may have limited the added value of the 
LoDED strategy. Finally, while the ratio-
nale for using the limit of detection is well 
supported by evidence from observational 
studies and recommended by interna-
tional guidelines, recent evidence suggests 
that higher risk stratification thresholds of 
cardiac troponin may have greater efficacy 
with similar safety.8
Although there may be some uncer-
tainty in the interpretation of the LoDED 
trial, it does provide important insights 
into the use of high- sensitivity troponin 
in the risk stratification of patients with 
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suspected acute coronary syndrome. A 
high degree of adherence to the new 
pathway (88% (95% CI 81% to 93%)) 
was observed, which likely reflects ease of 
applicability of the LoDED pathway and a 
high- level of confidence in the prognostic 
value of high- sensitivity cardiac troponin 
among clinicians. It is important to note 
that although patients were randomised to 
two different pathways, clinical decisions 
were made entirely at the discretion of the 
treating clinician. Furthermore, regard-
less of pathway allocation, no patients 
discharged with a troponin concentra-
tion below the limit of detection had a 
MACE outcome within 30 days. Although 
this study was not powered to evaluate 
safety, this further corroborates findings 
from observational studies on the excel-
lent prognostic value of very low cardiac 
troponin concentrations. Finally, LoDED 
included only those who presented within 
6 hours of symptom onset and therefore 
enriched for patients who presented early 
following the onset of chest pain, with a 
median of time from symptom onset to 
arrival of 2.3 hours (IQR, 1.5–3.6). A lack 
of evidence of harm is reassuring, but will 
need to be further investigated in future 
clinical trials enrolling a broader range 
of patients before recommending this 
approach for patients who present within 
3 hours of symptom onset.
In summary, the LoDED trial did not 
demonstrate that using a high- sensitivity 
cardiac troponin concentration below 
the limit of detection at presentation was 
more effective than usual care to rule- out 
myocardial infarction in the emergency 
department. Nevertheless, there were a 
number of encouraging insights which 
require further investigation. The LoDED 
trial and other randomised controlled 
trials addressing this topic6 are much 
needed to raise the quality of evidence 
used to inform national and interna-
tional clinical practice guidelines. These 
pathways are used to guide some of the 
most important decisions in practice, such 
as hospital admission for inpatient care, 
referral for specialist evaluation, selection 
for further diagnostic testing and prescrip-
tion of disease modifying therapies, which 
have profound implications on individual 
patient care and use of scarce hospital 
resources. Clinicians and healthcare 
systems must therefore demand nothing 
short of the highest quality of evidence 
from randomised trials to inform the 
implementation of these strategies.
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